Article
Shun-Long Ou, Jing Luo, Hua Wei, Xiao-Li, Qian Jiang
Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies
Summary
As the population ages, the incidence and prevalence of cancer are expected to continue to rise both in developed and developing countries. The estimated total annual economic cost of cancer was US$1.16 trillion in 2010, about 2% of global gross domestic product and is continuing to rise exponentially. Breast cancer remains the leading cause of cancer among women and the ongoing care of breast cancer patients is estimated to be one of the most significant contributors to growing cancer care expenditure.
These considerations underscore the need for validated tools to evaluate value of care, where value is recognised as a balance between clinical benefit and cost. With this in mind, both the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) established Working Groups to address these issues and they have developed and published a platform for evaluating new anticancer therapeutics—the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) and the ASCO Framework for assessing value of cancer care.
The ESMO-MCBS was initially launched and published in 2015 and revised in 2017 with version 1.1. The scale aims to provide a validated and rational stratification process for oncology therapies, and its development process has been predicated on ‘
accountability for reasonableness’ which incorporated extensive field testing and the peer review of results for ‘reasonableness’. Form 1 of the ESMO-MCBS, which is used to grade therapies with curative intent including adjuvant therapies, hitherto, has only been applied in a limited number of studies. Form 1 of the ESMO-MCBS grades therapies with curative intent on a three-point scale A, B and C where scores of A and B represent substantial improvement.
This is the first large-scale field testing of form 1 in early breast cancer to assess the applicability of the ESMO-MCBS in this setting, to determine whether the scoring reflected clinical practice (reasonableness) and to identify shortcomings to be addressed in future versions of the scale. It also provides an overview of the magnitude of benefit for the most common therapies/therapeutic strategies in the field of breast cancer, allowing for a critical reassessment of available options.
early breast cancer, magnitude of clinical benefit scale, ESMO-MCBS
Related Topics
You May Also Like
Shun-Long Ou, Jing Luo, Hua Wei, Xiao-Li, Qian Jiang
Article
Jing Luo, Shunlong Ou, Hua Wei, Xiaoli Qin, Rui Peng, Song Wang and Qian Jiang
Value assessment of NMPA-approved new cancer drugs for solid cancer in China, 2016-2020
Article
Jayson L. Parker, Sebnem S. Kuzulugil, Kirill Pereverzev, Stephen Mac, Gilberto Lopes, Zain Shah, Ashini Weerasinghe, Daniel Rubinger, Adam Falconi, Ayse Bener, Bora Caglayan, Rohan Tangri, Nicholas Mitsakakis
Does biomarker use in oncology improve clinical trial failure risk? A large-scale analysis
Article
Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
Article
Vanessa Arciero, BS, Seanthel Delos Santos, Liza Koshy
Assessment of Food and Drug Administration- and European Medicines Agency-Approved Systemic Oncology Therapies and Clinically Meaningful Improvements in Quality of Life: A Systematic Review
Article
iNIZIO